,

Aruna Bio
Coming November 29

A Breakthrough In The Treatment Of Parkinson's Disease

Date & Time


November 29, 4:00 PM ET / 1:00 PM PT
Webinar Details provided upon RSVP Approval

About the Event


Aruna Bio has developed an innovative neural anti-inflammatory and neuro-modulator that naturally crosses the Blood/Brain Barrier. This represents a major breakthrough in treating Central Nervous System (CNS) diseases like Parkinson’s, Alzheimer’s, Multiple Sclerosis, and acute events like Strokes and Traumatic Brain Injuries.

Join our panel discussion with:

  • Mason “Skip” Irving: Board Member of the Michael J. Fox Foundation for Parkinson’s Research
  • John Bishai, PhD: Managing Director – Healthcare Investment Banking – Bank of America Securities
  • Steven From, CEO, Aruna Bio

They’ll discuss the science that allows Aruna’s platform to cross the blood/brain barrier, its native therapeutic benefits, and how it can be used to deliver specialized neural therapeutics directly to the site of action.

Sign up today to learn what this breakthrough means for the for the millions of people suffering from some of the most debilitating diseases we face today.

Sign Up For This Event


SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.